China Medical System Holdings
China Medical System Holdings Limited, commonly known as CMS, is a specialty pharmaceutical service provider in China focused on product licensing, promotion, and sales. The company identifies, acquires, and commercializes specialty prescription drugs and aesthetic medical products across therapeutic fields such as cardiology, gastroenterology, dermatology, and ophthalmology. Revenue is predominantly derived from commercial product sales of licensed proprietary pharmaceuticals and medical aesthetic treatments to hospital and pharmacy distribution networks. CMS serves pharmaceutical brand owners, hospital networks, specialty medical clinics, dermatology practices, and retail pharmacies across mainland China and international markets. The enterprise holds an established market position as a premier specialty pharmaceutical commercialization platform in Greater China. China Medical System Holdings Limited is headquartered in Shenzhen, China, and its common shares are listed on the Stock Exchange of Hong Kong.
7 of the funds FundTelligence covers report a position in China Medical System Holdings.
- Legal name
- China Medical System Holdings Ltd
- Sector
- Health Care
- Country
- China
- Funds holding it
- 7
Funds holding China Medical System Holdings
- Nordea Stable Emerging Markets — Nordea Funds · 0.68 % (full portfolio disclosed, July 2026)
- Handelsbanken Emerging Markets Index — Handelsbanken · 0.03 % (full portfolio disclosed, September 2026)
- Storebrand Emerging Markets Plus — Storebrand · 0.02 % (full portfolio disclosed, October 2026)
- BlackRock iShares MSCI EM IMI Screened UCITS ETF — BlackRock · 0.01 % (full portfolio disclosed, October 2026)
- Handelsbanken Global Index Criteria — Handelsbanken · 0.01 % (full portfolio disclosed, September 2026)
- Storebrand Global All Countries — Storebrand · 0.0 % (full portfolio disclosed, October 2026)
- Storebrand Indeks Nye Markeder — Storebrand · 0.0 % (full portfolio disclosed, October 2026)